Organisation paid for research Program year 2025 Source: CMS Open Payments

Empire Eye and Laser Center

Neither a doctor nor a teaching hospital

Research payments

$303,767

67 payments

Through program year 2025, Empire Eye and Laser Center is reported as receiving $303,767 in research payments, across 67 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $2,064 3
2022 Research $12,295 12
2021 Research $33,190 16
2020 Research $30,084 13
2019 Research $226,134 23

Breakdown

Who paid Research payments · program years 2019–2025
  1. Johnson & Johnson Surgical Vision, Inc. $157,975 8 payments
  2. Glaukos Corporation $120,910 53 payments
  3. Novartis Pharmaceuticals Corporation $21,210 2 payments
  4. Oyster Point Pharma, Inc. $2,052 2 payments
  5. AbbVie, Inc. $1,607 1 payment
  6. Harrow Eye, LLC $12 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Drye-102-Self $76,600 5 payments
  2. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $68,159 15 payments
  3. Mdev-101-Test $40,000 1 payment
  4. Mdev-102-Test $32,000 1 payment
  5. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $30,084 13 payments
  6. A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study to Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 MG/ML and 15 MG/ML) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced Chronic Pain (Cicp) Following Photorefractive Keratectomy (PRK) Or Laser-Assisted in Situ Keratomileusis (Lasik) Surgeries $17,160 1 payment
  7. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $12,680 11 payments
  8. Tiol-205-Stpa $9,375 1 payment
  9. A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study to Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 MG/ML and 15 MG/ML) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced $4,050 1 payment
  10. iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study $1,742 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record